{"filings":[{"id":1029446,"accession_number":"0001628280-26-042932","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-06-12T21:00:14+00:00","items":["5.07"],"status":"ready","headline":"All six director nominees elected, Deloitte ratified, say-on-pay approved at Ginkgo 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders present: 39.5M Class A and 8.4M Class B shares, representing 77.15% of combined voting power.","All six directors elected: Jason Kelly and Reshma Shetty (Class B vote), Ross Fubini, Christian Henry, Sri Kosuri, Harry E. Sloan (single class).","Ratification of Deloitte & Touche as auditor for FY2026 approved: 119.5M for, 267k against, 3.8M abstentions.","Advisory vote to approve executive compensation passed: 95.1M for, 12.5M against, 4.2M abstentions (broker non-votes 11.8M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95967,"accession_number":"0001628280-26-032093","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $19M, down 49% YoY; prior year included $7M non-cash deferred revenue release; adjusted EBITDA -$42M.","GAAP net loss from continuing ops -$76M (vs -$83M prior year); operating cash burn trajectory reaffirmed.","Completed Biosecurity divestiture on April 3, 2026; results presented as discontinued ops.","Cash, cash equivalents and marketable securities $373M as of March 31, 2026.","Reaffirms FY 2026 total cash burn guidance of $(150)-$(125) million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":19474000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95966,"accession_number":"0001628280-26-024101","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Ginkgo completes sale of Biosecurity segment to Tower Biosecurity, retains 20% stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On April 3, 2026, Ginkgo contributed all Biosecurity equity to Tower Biosecurity (Perimeter Systems) for ~20% of buyer's fully diluted shares.","Biosecurity will be reported as discontinued operations starting Q1 2026; pro forma results show reduced operating losses.","Pro forma 2025 net loss improved to $287.8M from $312.8M; 2024 loss improved to $507.6M from $547.0M.","The retained 20% stake will be equity-method accounted; preliminary valuation of $12.3M.","Ginkgo and Tower entered a Transition Services Agreement for temporary services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109434,"accession_number":"0001628280-26-012552","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks sells Biosecurity segment to Tower Biosecurity for 20% stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ginkgo contributes all equity of Ginkgo Biosecurity, LLC (its Biosecurity segment) to Tower Biosecurity.","In exchange, Ginkgo receives shares representing ~20% of Tower Biosecurity on a fully diluted basis.","Transaction expected to close in first half of 2026, subject to customary closing conditions.","Seller is Ginkgo Bioworks, Inc.; parent Ginkgo Bioworks Holdings is party for limited purposes.","No cash purchase price disclosed; consideration is solely an equity stake in the acquirer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109433,"accession_number":"0001628280-26-012339","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q4 revenue $33M (-24% YoY); announces biosecurity spin-off, FY2026 cash burn guidance $150-125M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $33M, down 24% YoY; Cell Engineering $26M (-26%), Biosecurity $7M (-22%).","GAAP net loss $(81)M improved from $(108)M; Adjusted EBITDA $(36)M vs $(57)M.","Full year 2025 revenue $170M (-25%); GAAP net loss $(313)M; Adjusted EBITDA $(167)M; cash $423M.","Announced divestiture of biosecurity business to investor consortium for minority equity stake; expected close H1 2026.","Strategic focus on autonomous labs; decommissioning lab benches; collaborations with OpenAI and PNNL ($47M contract). FY2026 cash burn guidance $(150)-$(125)M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":170155000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125924,"accession_number":"0001628280-25-058791","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Ginkgo Bioworks COO Reshma Shetty transitions role; Jennifer Wipf assumes ops duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Reshma Shetty steps down as COO effective Jan 1, 2026; remains President and Board member.","She will focus on expanding autonomous lab for cell engineering service offerings.","CEO Dr. Jason Kelly assumes principal operating officer oversight duties.","Jennifer Wipf (ex-CCO/GM) takes on day-to-day operations, reporting to Kelly.","Wipf brings vaccine and plant management experience from over a decade at Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125923,"accession_number":"0001830214-25-000013","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q3 revenue $39M (-56% YoY); net loss $81M; reaffirms FY guide $167-187M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $39M, down 56% YoY; prior year had $45M non-cash deferred revenue; ex that, down 11%.","GAAP net loss $81M vs $56M prior; Adjusted EBITDA loss $56M vs $20M.","Reaffirms FY25 revenue $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M.","Cash & securities $462M; expands autonomous lab; Bayer partnership extended, BARDA contract up to $22.2M.","Cell Engineering revenue $29M (-61% YoY); Biosecurity $9M ($14M prior)."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":136759000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142676,"accession_number":"0001830214-25-000009","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks enters $100M at-the-market equity sales agreement with Allen & Company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100M in Class A common stock may be sold through Agent Allen & Company.","Agent receives commission of up to 3% of gross proceeds from each sale.","Registration statement on Form S-3 declared effective August 14, 2025; prospectus supplement dated Sept 4, 2025.","Net proceeds to be used for general corporate purposes including operations, tech development, working capital.","Company may terminate Sales Agreement with sufficient written notice; no assurance any shares will be issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142675,"accession_number":"0001628280-25-041399","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Court grants preliminary approval to Ginkgo Bioworks derivative settlement; $4.125M from insurance","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company receives $4.125M from insurance; plaintiffs' counsel may request $2.75M in fees.","Settlement requires Ginkgo to adopt corporate governance reforms.","Derivative actions (Hu, Bowers, In re Ginkgo) will be dismissed with prejudice.","Final hearing set for December 18, 2025; settlement entered on May 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142674,"accession_number":"0001628280-25-038981","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q2 2025 revenue $50M, net loss $60M; achieves $250M cost savings goal ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $50M, down from $56M YoY; Cell Engineering rev up 8% to $39M; Biosecurity down to $10M.","GAAP net loss $60M, improved from $217M YoY; Adjusted EBITDA -$28M, up from -$99M.","Achieved $250M annualized cost reduction target three months ahead of schedule.","Cash, equivalents, marketable securities $474M as of June 30, 2025.","Reaffirmed FY2025 total revenue outlook $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":97922000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160738,"accession_number":"0001628280-25-031304","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ginkgo Bioworks shareholders elect all seven director nominees at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected, including Jason Kelly and Reshma Shetty (Class B) and five others.","Ratification of Deloitte & Touche as independent auditor for FY2025 approved with 118.2M votes for.","Advisory vote on executive compensation passed with 107.2M votes for (approx. 99.2% of votes cast).","Three proposals passed; no broker non-votes on ratification and advisory votes were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160737,"accession_number":"0001628280-25-027058","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Ginkgo CFO Dmytruk to resign May 30; CAO Coen appointed CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Dmytruk resigns as CFO, effective May 30, 2025, to accept a position at another organization.","Steven Coen, CAO, becomes CFO, principal financial officer, and principal accounting officer.","Coen has 30+ years of experience, previously EVP & Corporate Controller at Charles River Labs, and audit at Deloitte.","Coen's base salary is $460,000; he receives a PSU award of 67,991 shares tied to 2025 cash flow objectives.","Coen joined Ginkgo in May 2023 and is a CPA in Massachusetts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160736,"accession_number":"0001628280-25-022759","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks Q1 revenue up 27% to $48M, guided revenue raised; net loss narrows to $91M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 total revenue $48M (+27% YoY); core revenue ex-deferred release $41M (+8%). GAAP net loss $(91)M vs $(166)M prior year.","Adjusted EBITDA $(47)M improved from $(117)M; cash & equivalents $517M.","Raises FY2025 total revenue guidance to $167-187M (from $160-180M); Cell Eng. guidance $117-137M.","Cost reduction target: $250M annualized by Q3 2025; achieved $205M run-rate in Q1.","Awarded $29M ARPA-H contract for distributed manufacturing using wheat germ cell-free systems."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":48318000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178937,"accession_number":"0001628280-25-007816","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q4 2024 revenue $44M (+26% YoY); net loss improves to $(108)M; 2025 rev guidance $160-180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $44M (up 26% YoY); Cell Engineering rev $35M (+29% YoY), Biosecurity $9M.","GAAP net loss $(108)M vs $(212)M in Q4 2023; Adj EBITDA $(57)M vs $(101)M.","Cash flow $(55)M in Q4, improved from $(114)M in Q3; cash balance $562M.","FY2025 guidance: total revenue $160-180M, Cell Engineering $110-130M, Biosecurity at least $50M.","Cost-cutting achieved $190M annualized run-rate savings; targeting $250M by Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":227043000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195619,"accession_number":"0001628280-24-047276","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Ginkgo Q3 total rev $89M (+61% YoY) includes $45M deferred release; core $44M (-21%); guides FY $215-235M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $89M (+61% YoY) incl. $45M non-cash deferred revenue; core rev $44M (-21%).","Cell Engineering ex-deferred $30M (-20% YoY); Biosecurity $14M with 28% gross margin.","Loss from ops $(55)M vs $(286)M; Adj EBITDA $(20)M vs $(84)M.","FY24 guidance raised: Total rev $215-235M, Cell Eng $165-185M, Biosecurity ≥$50M.","Appointed Dr. Sri Kosuri to Board; Dr. Belldegrun resigned. Signed deal with Novo Nordisk; Merck milestone $9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":183196000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211877,"accession_number":"0001628280-24-039341","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"NYSE to delist Ginkgo Bioworks warrants for abnormally low price; common stock regains compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE notified Ginkgo on Sept 3, 2024 to delist warrants (DNA.WS) due to 'abnormally low' trading prices; trading suspended immediately.","Common stock (DNA) unaffected and continues trading normally on NYSE.","Ginkgo regained compliance with NYSE minimum price rule on Aug 30, 2024; closing price above $1.00 for 30-day average.","Company removed from NYSE noncompliant issuers list for common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211876,"accession_number":"0001628280-24-037685","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ginkgo Bioworks files 1-for-40 reverse stock split effective August 19, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of all common stock classes at a 1:40 ratio, effective August 19, 2024.","Charter amended to add officer exculpation under new Article VIII.","Removed legacy provisions related to Soaring Eagle merger and domestication process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211875,"accession_number":"0001628280-24-037384","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Ginkgo Bioworks shareholders approve reverse split; board sets 1:40 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved by shareholders (4.7B votes for); board set ratio at 1:40.","Split effective Aug 19; shares trade split-adjusted Aug 20 under symbol DNA.","Every 40 shares of Common Stock combined into 1; fractional shares paid in cash.","Warrants adjusted: exercise price $460/share (or $11.50 per warrant); 40 warrants per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211874,"accession_number":"0001628280-24-036226","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K/A","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Ginkgo Q2 revenue down 30% to $56M, launches RIF cutting 35% of workforce for >$85M annual savings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $56M vs $81M YoY; Cell Engineering $36M (-20%), Biosecurity $20M (41% gross margin).","Loss from ops $(223)M incl. $72M restructuring costs; Adjusted EBITDA $(99)M vs $(80M) prior year.","Reduction in force impacting 35% of workforce, expected to yield >$85M annualized savings by mid-2025.","Restructuring costs estimated $18-22M in Cell Engineering; facilities consolidation underway.","FY 2024 outlook reaffirmed: total revenue $170-190M, Cell Engineering $120-140M, Biosecurity ≥$50M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":94150000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230668,"accession_number":"0001628280-24-029635","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K/A","filed_at":"2024-06-24T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Ginkgo Bioworks expands restructuring: at least 35% workforce reduction, $12M+ severance costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction expanded from 25% labor expense cut to 35% headcount reduction; implementation began June 17, 2024.","Expected cash costs of at least $12 million in severance and related separation costs for initial June reductions.","Substantially completed in 2025, subject to local laws; total costs not yet estimated.","Facility consolidation also planned as part of multi-year cost reduction plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230671,"accession_number":"0001628280-24-028287","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ginkgo Bioworks shareholders elect all 9 directors and approve auditor and say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of ~82.93% combined Class A and Class B shares; ~92.33% of Class B shares present.","All nine director nominees elected: Jason Kelly, Reshma Shetty, Arie Belldegrun, Ross Fubini, Kathy Hopinkah Hannan, Christian Henry, Myrtle Potter, Shyam Sankar, Harry E. Sloan.","Ratification of Deloitte & Touche as independent auditor for FY 2024 approved with 4,898,828,240 votes for.","Advisory vote to approve executive compensation passed with 4,583,064,713 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230670,"accession_number":"0001628280-24-022896","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks receives NYSE delisting notice for stock price below $1 for 30 trading days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE notified Ginkgo on May 7, 2024 that average closing price of Class A common stock was below $1.00 over 30 consecutive trading days.","No immediate delisting; six-month cure period to regain compliance by closing at $1.00 or above on last trading day of any calendar month.","Stock continues trading on NYSE under symbol 'DNA' with '.BC' designation indicating non-compliance.","Company intends to regain compliance and is evaluating all available options; business operations unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230669,"accession_number":"0001628280-24-022191","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Ginkgo Bioworks Q1 revenue $38M (-53% YoY), plans $200M cost cuts, targets EBITDA breakeven by end 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $38M, down 53% YoY; Cell Engineering $28M (-18%), Biosecurity $10M.","Loss from operations $178M (incl. $42M SBC); Adj. EBITDA -$100M, flat YoY; cash $840M, no debt.","Restructuring: reduce annualized opex by $200M by mid-2025, cut labor >=25%, consolidate facilities up to 60%.","Targeting adjusted EBITDA breakeven by end-2026; 2024 revenue guidance lowered to $170-190M.","Added 17 new Cell Programs in Q1; expects at least 100 new customer projects in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":37944000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249037,"accession_number":"0001628280-24-011216","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks replaces auditor: EY declines reappointment, Deloitte hired","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY notified Ginkgo on March 8, 2024 it would not stand for reappointment as auditor for fiscal 2024; no disagreement cited.","Audit Committee appointed Deloitte & Touche as new independent auditor on March 13, 2024.","EY's reports for FY 2022 and 2023 were unqualified; no adverse opinions or scope limitations.","Material weaknesses in internal control over financial reporting were disclosed for both 2022 and 2023, as previously reported.","No disagreements or reportable events (other than the material weaknesses) occurred during the relevant periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249036,"accession_number":"0001628280-24-008045","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks FY2023 revenue $251M (-47% YoY); guides FY2024 total revenue $215-235M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cell Engineering services revenue $139M (+31% YoY); added 78 new Cell Programs in 2023.","Biosecurity revenue $108M (-68% YoY) as K-12 testing ramped down; shifting to recurring model.","Q4 2023 total revenue $35M (-65% YoY); Q4 Adj. EBITDA loss $(96)M vs. $(76)M prior year.","Cash balance $944M; FY2024 guidance: 100-120 new Cell Programs; total revenue $215-235M.","Acquired Patch Biosciences, Proof Diagnostics, Reverie Labs; launched Technology Network of 25+ partners."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":251455000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249035,"accession_number":"0001628280-24-001000","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks expects to meet 2023 revenue guidance of $250-260M; cash nearly $950M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary cell engineering revenue $145-150M, biosecurity up to $110M, total revenue $250-260M.","New Cell Programs added expected within 80-85 range, meeting prior guidance.","Biopharma partnerships with Pfizer, Novo Nordisk, Merck, Boehringer Ingelheim; aggregate potential over $1.2B milestones.","Ended 2023 with nearly $950M cash and cash equivalents; strong balance sheet.","Full year 2023 financial results to be reported in February 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":251455000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266569,"accession_number":"0001628280-23-037916","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q3 2023: Total revenue $55M (-17% YoY); Cell Engineering up 51%; revises FY23 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cell Engineering revenue $37M (+51% YoY); Biosecurity revenue $18M with 62% gross margin.","Loss from ops $(286)M including $96M impairment charge; Adj. EBITDA $(84)M vs $(72)M prior year.","Added 21 new Cell Programs in Q3, 40% growth YoY; full-year target revised to 80-85 programs.","New partnerships: Pfizer RNA drug discovery (up to $331M milestones) and Google Cloud AI deal.","FY23 revenue guidance cut to $250-260M; Cell Engineering $145-150M; Biosecurity up to $110M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":216700000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266568,"accession_number":"0001193125-23-265256","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ginkgo Bioworks amends bylaws to tighten director nomination and stockholder proposal rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["New requirement that nominating stockholders comply with Rule 14a-19 (universal proxy rules).","Expanded disclosures required from director nominees and nominating stockholders, including ownership and interests.","Nominees must use a proxy card color other than white for their solicitations.","Removed requirement to maintain a stockholder list at meetings, per updated Delaware law.","All amendments effective immediately as of October 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266567,"accession_number":"0001628280-23-033551","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Zymergen subsidiary files Chapter 11; Ginkgo to acquire IP assets as stalking horse bidder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zymergen Inc., a wholly-owned subsidiary of Ginkgo, filed voluntary Chapter 11 petitions on October 3, 2023 in Delaware.","Neither Ginkgo nor its other subsidiaries filed for bankruptcy; Ginkgo remains well capitalized with $1.1B cash as of Q2 2023.","Ginkgo entered an asset purchase agreement as stalking horse bidder to acquire exclusive rights to substantially all Zymergen IP assets.","Bid includes $5M cash and assumption of up to $77M in future liabilities (lease, employee compensation and severance).","Existing non-exclusive license for Zymergen's databases, automation, and software remains unaffected by the bankruptcy process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283808,"accession_number":"0000950170-23-044892","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks partners with Google Cloud for AI biology tools; up to $56.3M funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five-year partnership to develop large language models for biology on Google Cloud's Vertex AI platform.","Minimum annual cloud commitments: $8M (Y1), $28M (Y2), $54M (Y3), $86M (Y4), $113M (Y5).","Google Cloud provides up to $56.3M in milestone-based cash funding over three years.","Ginkgo intends to make Google Cloud its primary cloud services provider.","First planned model: a foundation model for proteins, targeting drug discovery and biosecurity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283807,"accession_number":"0001193125-23-219091","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ginkgo files updated pro forma financials for Zymergen acquisition; pro forma net loss $2.4B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma combined revenue $487.8M for FY 2022; Ginkgo standalone $477.7M, Zymergen $10.1M.","Pro forma net loss attributable to Ginkgo stockholders $2.405B; diluted EPS loss $1.37.","Adjustments include $8.1M net reduction in operating expenses from fair value and compensation changes.","Weighted average shares outstanding increased to 1.76B from 1.68B due to Merger consideration shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283806,"accession_number":"0000950170-23-040716","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q2 revenue $81M (-44% YoY); Cell Engineering services up 72%; guides FY23 rev $245-260M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $81M, down 44% YoY as Biosecurity K-12 testing wound down.","Cell Engineering services revenue $44M, up 72% YoY; total Cell Engineering $45M.","Biosecurity revenue $35M (49% gross margin); expanding internationally.","Adjusted EBITDA loss $(75)M; operating loss $(184)M including $62M stock comp.","FY23 guidance: total rev $245-260M, Cell Eng rev revised to $145-160M, Bio at least $100M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":161270000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303385,"accession_number":"0000950170-23-028975","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ginkgo Bioworks shareholders elect nine directors; ratify EY; approve say-on-pay and annual frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected: Jason Kelly and Reshma Shetty by Class B holders; remaining seven by combined class.","Ratification of Ernst & Young as independent auditor approved: 4.55B votes for, 9.2M against.","Advisory vote on executive compensation passed: 4.33B for, 11.5M against.","Annual frequency for say-on-pay votes selected: 4.33B votes supported 1-year interval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303384,"accession_number":"0000950170-23-020490","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks Q1 revenue $81M, down 52% YoY; Cell Engineering rev up 59%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 total revenue $81M (down 52% YoY); Cell Engineering rev $34M (+59% YoY); Biosecurity rev $47M (52% gross margin).","Operating loss $(216)M (incl. $75M SBC); Adj. EBITDA $(100)M vs $(1)M prior year. Cash ~$1.2B.","Added 13 new Cell Programs (18% YoY growth); FY2023 outlook: at least 100 new programs, total rev ≥$275M.","Acquired StrideBio's AAV capsid engineering platform to advance gene therapy capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":80702000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303383,"accession_number":"0000950170-23-018074","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks appoints Steven Coen as Chief Accounting Officer; Marie Fallon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marie Fallon resigns as CAO effective May 15, 2023; she will remain through June 2 and then as consultant.","Steven Coen appointed CAO effective same date, with annual base salary of $400,000 and $1.5M equity grant vesting over 4 years.","Coen brings over 30 years experience, most recently Corporate VP & Controller at Charles River Laboratories (annual revenues ~$4B).","Fallon's resignation is personal, not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323002,"accession_number":"0000950170-23-007359","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Ginkgo Bioworks discloses ~$74M exposure to failed Silicon Valley Bank via Zymergen subsidiary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zymergen subsidiary holds ~$74M (6% of total cash) at Silicon Valley Bank.","SVB closed and FDIC appointed receiver as of March 10, 2023.","Company has no other material accounts or credit lines with SVB.","Cash reference point: $74M based on Dec 31, 2022 balance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323001,"accession_number":"0000950170-23-005511","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks reports 2022 revenue up 52% to $478M; guides 2023 total revenue at least $275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2022 total revenue $478M (+52% YoY); Foundry $144M (+27%), Biosecurity $334M (+66%).","Adjusted EBITDA loss widened to $(173)M in 2022 from $(106)M in 2021; operating loss $(2.2)B includes $1.9B stock comp.","2023 guidance: 100 new Cell Programs; total revenue at least $275M (Foundry ≥$175M, Biosecurity ≥$100M).","Cash and equivalents over $1.3B; filing extension for 10-K due to becoming large accelerated filer.","Added 59 new Cell Programs in 2022 (90% growth); downstream milestone potential added over $2.0B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":477706000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323000,"accession_number":"0001193125-23-017551","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ginkgo files Zymergen Q3 2022 financials; net loss $75.7M on $2.3M revenue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zymergen Q3 2022: revenue $2.3M, net loss $75.7M, operating loss $75.3M.","Nine-month 2022: revenue $9.7M, net loss $264.3M, operating loss $245.1M.","Cash $153.4M at Sep 30, 2022, down from $386.1M at Dec 31, 2021.","Goodwill impairment charge of $40.6M recorded during 2022.","Going-concern doubt that existed at June 30, 2022 alleviated by Oct 19, 2022 merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322999,"accession_number":"0000950170-23-000640","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo expects to meet 2022 total revenue guidance of $460-480M; cash ~$1.3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expects 55-60 new Cell Programs added in 2022, nearly doubling 2021 additions.","Foundry revenue expected below $150-170M guidance; Biosecurity revenue exceeds $310M.","Ended 2022 with approx. $1.3B cash; strong liquidity despite challenging macro.","Opened Bioworks7 (6,600 sq ft BSL-2 lab) for mammalian cell engineering; launched Ginkgo Enzyme Services.","Full audited Q4 and FY 2022 results due March 2023; 2023 outlook to be provided then."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":477706000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341075,"accession_number":"0001193125-22-289107","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks closes $99.1M bought-deal equity offering of 41.4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bought deal of 41,383,877 shares at $2.4164/share; net proceeds ~$99.1M after expenses.","Underwriter granted 30-day option to purchase up to 6,207,581 additional shares at same price.","Proceeds offset $80M cash used for Bayer CropScience asset acquisition and strengthen balance sheet.","Offering closed on November 18, 2022; underwriter BTIG, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341074,"accession_number":"0000950170-22-024981","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q3 rev down 14% to $66M; raises FY22 revenue guidance to $460-480M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $66M (down 14% YoY); Foundry $25M (down 29%), Biosecurity $42M (down 3%).","Operating loss $(653)M includes $563M stock-based comp; Adj EBITDA $(70)M vs $(18)M prior year.","Added 15 new Cell Programs (50% growth); cash & equivalents over $1.3B.","Completed Zymergen, Bayer West Sac, Altar, and Circularis acquisitions in October.","FY22 guidance raised: total rev $460-480M (from $425-440M), Biosecurity at least $310M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":379421000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341073,"accession_number":"0001193125-22-264928","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks completes acquisition of Zymergen; exchange ratio 0.9179","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed on October 19, 2022, per the merger agreement signed July 24, 2022.","Zymergen stockholders received 0.9179 Ginkgo Class A shares per Zymergen share held.","Zymergen shares will cease trading on Nasdaq; Ginkgo common stock continues on NYSE as DNA.","Expected to enhance Ginkgo's platform with added automation, software, and biological engineering expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341072,"accession_number":"0001193125-22-257692","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ginkgo recasts 2021 financials into Foundry and Biosecurity segments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Historical segment data revised to two segments: Foundry and Biosecurity (previously one segment).","No changes to previously reported total revenue, net income, or cash flows.","Segment change was implemented in Q1 2022; this filing provides recast comparative periods.","Recast information intended for incorporation by reference into future registration statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358204,"accession_number":"0000950170-22-017376","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q2 revenue $145M (+231% YoY); guides total revenue to $425-440M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Foundry revenue $44M (+105% YoY); added 13 new Cell Programs in Q2.","Biosecurity revenue $100M with 36% gross margin; expects at least $260M for FY 2022.","Adjusted EBITDA improved to -$23M from -$38M YoY; cash balance ~$1.4B.","Pending acquisitions of Zymergen (all-stock) and Bayer's West Sacramento facility expected to close Q4 2022 / Q1 2023.","Dr. Kathy Hopinkah Hannan appointed to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":313023000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358203,"accession_number":"0000950170-22-014468","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks appoints Kathy Hopinkah Hannan to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective August 2, 2022; term expires at 2023 annual meeting.","Received options to purchase Class A common stock valued at $400,000 plus prorated RSUs and options.","Eligible for $50,000 annual retainer and annual stock awards under Non-Employee Director Compensation Program.","Hannan is retired KPMG Vice Chair and serves on boards of NLY, OTIS, and CRS.","Board determined Dr. Hannan is independent under NYSE listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358202,"accession_number":"0001193125-22-200433","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ginkgo to acquire Zymergen for ~$300M all-stock; Zymergen holders get 0.9179 DNA shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal valued at ~$300M market cap; fixed exchange ratio of 0.9179 Ginkgo shares per Zymergen share.","Zymergen stockholders will own 5.25% of pro forma combined company after transaction close.","Voting agreements from holders of ~40% of Zymergen shares to vote in favor of the merger.","Integration expected to accelerate Ginkgo's platform; Zymergen to evaluate strategic alternatives for Advanced Materials and Drug Discovery.","Transaction subject to regulatory approvals, Zymergen stockholder vote, and other conditions; expected close by Jan 24, 2023 with extension options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358201,"accession_number":"0001193125-22-200429","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Ginkgo to acquire Bayer's agricultural biologics R&D platform for ~$83M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ginkgo acquires Bayer's 175,000 sq ft West Sacramento Biologics R&D site and team for ~$83M in cash or stock.","Three-year strategic partnership with Bayer on nitrogen fixation, crop protection, and carbon sequestration.","Ginkgo to also integrate Joyn Bio R&D platform assets; deal expected to close Q4 2022.","Ginkgo may earn royalties on net sales from products developed under the Bayer collaboration.","Expands Ginkgo's agricultural biologicals platform; cash proceeds from collaboration offset acquired expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376927,"accession_number":"0000950170-22-011589","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ginkgo Bioworks shareholders elect eight directors and ratify EY at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 81.47% of combined Class A and Class B voting power; 859.9M Class A and 351.5M Class B shares present.","All eight director nominees elected: Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar, Harry E. Sloan.","Ratification of Ernst & Young as independent auditor for FY2022 approved with 4,365,263,156 votes for and 5,152,427 against.","Annual meeting held June 10, 2022; no other proposals or director nominations brought before shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376926,"accession_number":"0000950170-22-010067","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q1 revenue $168M (+282% YoY); raises FY22 total revenue guidance to $375-390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $168M (+282% YoY); Foundry revenue $21M (-5% YoY); Biosecurity revenue $147M.","Loss from operations $(675)M incl. $659M stock comp; Adj. EBITDA $(2)M improved from $(51)M.","Added 11 new Cell Programs in Q1; FY22 target of 60 new programs unchanged.","Raised FY22 total revenue guidance to $375-390M from $325-340M; Foundry guidance unchanged.","Announced plans to acquire Bayer's West Sacramento ag biologics site and flagship collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":168405000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395276,"accession_number":"0000950170-22-004778","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks FY2021 revenue $314M (+309% YoY); 2022 guidance $325-340M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2021 total revenue $314M, up 309% YoY; Foundry revenue $113M (+91%), Biosecurity $201M (exceeded $110M outlook).","Added 31 new Cell Programs in 2021 (+72% YoY); 2022 guidance expects 60 new programs.","Q4 2021 total revenue $148M vs $32M YoY; Adjusted EBITDA $1M vs $(51)M in prior year.","GAAP loss from ops $(1.8)B including $1.7B catch-up stock comp; cash balance >$1.5B.","Announced two tuck-in acquisitions in 2022: Project Beacon (COVID testing) and FGen (strain optimization)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":568976290.7606444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-28T23:59:59+00:00|395276"}